Current US Dengue Statistics 2025
As of 2025, the Centers for Disease Control and Prevention (CDC) has reported 2,096 confirmed dengue cases across the United States. This data is compiled through the CDC’s ArboNET system, which monitors and reports on arboviral diseases nationwide. These figures reflect both travel-related and locally acquired cases, underscoring the importance of continued vigilance in both tropical and subtropical areas where the Aedes mosquito is active.
The current spike in cases raises public health concerns, especially in states like Florida, Texas, and California where climate and population density create favorable conditions for mosquito-borne transmission. Health authorities continue to stress preventive measures such as mosquito control, public education, and timely reporting of symptoms. As global travel resumes post-pandemic and climate conditions shift, dengue remains a growing threat even in traditionally low-risk regions of the U.S.
| Metric | Value |
|---|---|
| Total Cases in 2025 | 2,096 |
| Total Cases (2010-2024) | 55,767 |
Clinical Presentation and Severity 2025
The clinical syndrome breakdown reveals important patterns in disease severity:
- 91% presented as standard dengue fever (approximately 1,907 cases)
- 6% presented as dengue-like illness (approximately 126 cases)
- 3% developed severe dengue (approximately 63 cases)
| Clinical Syndrome | Percentage | Approximate Cases | Severity Level |
|---|---|---|---|
| Dengue Fever | 91% | 1,907 | Standard |
| Dengue-Like Illness | 6% | 126 | Mild |
| Severe Dengue | 3% | 63 | Critical |
| Total | 100% | 2,096 | – |
The 3% severe dengue rate, while relatively small, represents a significant number of patients requiring emergency medical care, as severe dengue is a medical emergency according to CDC guidelines.
Dengue in the US – Demographics: Age Distribution
Age Distribution
The 2025 data shows dengue affects all age groups, with notable patterns:
| Age Group | Male (%) | Female (%) | Combined Risk Level |
|---|---|---|---|
| < 1 year | 0% | 0% | Very Low |
| 1-10 years | 5% | 4% | Moderate |
| 11-19 years | 16% | 13% | Highest |
| 20-29 years | 8% | 8% | High |
| 30-39 years | 5% | 6% | Moderate |
| 40-49 years | 5% | 5% | Moderate |
| 50-59 years | 5% | 4% | Moderate |
| 60-69 years | 4% | 4% | Low |
| 70+ years | 4% | 3% | Low |
| Unknown | 0% | 0% | – |
Highest Risk Groups:
- 11-19 years: 16% (male) and 13% (female) – representing the highest affected age group
- 20-29 years: 8% for both males and females
- 1-10 years: 5% (male) and 4% (female)
Lower Risk Groups:
- Adults over 70: 4% (male) and 3% (female)
- Infants under 1 year: Less than 1% for both sexes
Dengue Hospitalization Rates 2025
Healthcare utilization data shows:
- 45% of patients were hospitalized
- 23% were not hospitalized
- 32% had unknown hospitalization status
| Hospitalization Status | Percentage | Approximate Cases | Healthcare Impact |
|---|---|---|---|
| Hospitalized | 45% | 943 | High |
| Not Hospitalized | 23% | 482 | Low |
| Unknown Status | 32% | 671 | – |
| Total | 100% | 2,096 | – |
The high hospitalization rate (45%) indicates that many dengue cases in the US require significant medical intervention, reflecting either more severe disease presentation or cautious clinical management practices.
Travel Status and Local Transmission
While the specific travel-associated versus locally acquired case breakdown wasn’t detailed in the current data, the CDC notes that most dengue cases in the 49 continental US states historically occur in travelers. However, recent years have seen increasing local transmission in states like Florida, Texas, California, Hawaii, and Arizona.
| Transmission Type | Historical Pattern | 2025 Trend | States Affected |
|---|---|---|---|
| Travel-Associated | Majority of cases | Continuing | All 50 states |
| Locally Acquired | Rare, emerging | Increasing | FL, TX, CA, HI, AZ |
| Unknown Source | Variable | Under investigation | Multiple states |
Historical Dengue Trends in the United States (2010-2024)
The 15-year surveillance data from 2010-2024 provides crucial context for understanding the current 2025 dengue situation, revealing significant patterns in both travel-associated and locally acquired cases.
Overall Historical Summary (2010-2024)
| Historical Metric | Value | Significance |
|---|---|---|
| Total Cases (2010-2024) | 55,767 | Substantial 15-year burden |
| Jurisdictions Reporting | 59 | Widespread geographic impact |
| Annual Average | 3,718 cases/year | Baseline transmission level |
| 2025 Cases | 2,096 | On track for above-average year |
Travel-Associated Cases: Historical Trends (2010-2024)
| Year | Travel Cases | Notable Trends |
|---|---|---|
| 2010 | 642 | Baseline level |
| 2011 | 243 | Significant drop |
| 2012 | 545 | Recovery |
| 2013 | 794 | Moderate increase |
| 2014 | 667 | Stable |
| 2015 | 751 | Gradual increase |
| 2016 | 919 | Peak pre-2019 |
| 2017 | 451 | Decline |
| 2018 | 483 | Stable low |
| 2019 | 1,474 | Major surge begins |
| 2020 | 354 | COVID-19 impact |
| 2021 | 205 | Historic low |
| 2022 | 1,494 | Recovery surge |
| 2023 | 1,890 | Continued increase |
| 2024 | 3,684 | Record high |
Key Travel-Associated Trends:
- 2024 represented a historic peak with 3,684 travel-associated cases, nearly double 2023 levels
- COVID-19 impact clearly visible in 2020-2021 with dramatic reductions due to travel restrictions
- Post-pandemic surge beginning in 2022, accelerating through 2024
Locally Acquired Cases: Historical Patterns (2010-2024)
| Year | Local Cases | Outbreak Status |
|---|---|---|
| 2010 | 10,969 | Major outbreak |
| 2011 | 1,552 | Decline |
| 2012 | 6,169 | Secondary surge |
| 2013 | 9,933 | Near-record levels |
| 2014 | 551 | Sharp decline |
| 2015 | 261 | Low transmission |
| 2016 | 289 | Stable low |
| 2017 | 520 | Slight increase |
| 2018 | 156 | Minimal activity |
| 2019 | 119 | Historic low |
| 2020 | 983 | Unexpected surge |
| 2021 | 609 | Continued activity |
| 2022 | 1,046 | Moderate increase |
| 2023 | 1,462 | Rising trend |
| 2024 | 6,552 | Second highest on record |
Critical Local Transmission Insights:
- 2010-2013 represented a major endemic period with over 10,000 local cases in 2010 and nearly 10,000 in 2013
- 2014-2019 showed minimal local transmission (under 1,000 cases annually)
- 2020-2024 marked a concerning resurgence with 2024 recording 6,552 local cases – the second highest in the surveillance period
- Establishment risk increasing as local transmission becomes more frequent and geographically widespread
Public Health Implications
The 2025 US dengue data reveals several concerning trends when viewed against the historical context:
| Key Finding | 2025 Data | Historical Context | Public Health Concern Level |
|---|---|---|---|
| Total Cases | 2,096 | 55,767 cases (2010-2024) | High – Above average pace |
| Projected Annual Total | ~4,200 (estimated) | 3,718 annual average | High – 13% above average |
| Hospitalization Rate | 45% | No historical comparison | Critical – Healthcare burden |
| Severe Dengue | 3% (63 cases) | No historical comparison | High – Emergency care needs |
| DENV-3 Dominance | 85% of known serotypes | Serotype data limited | Moderate – Outbreak potential |
| Local Transmission Trend | Increasing pattern | 6,552 local cases in 2024 | Critical – Endemic risk |
Historical Context Analysis
Epidemic Cycles Identified:
- 2010-2013: First Major Endemic Period – Peak local transmission with over 10,000 cases in 2010
- 2014-2019: Minimal Activity Period – Consistently low local transmission (under 1,000 annually)
- 2020-2024: Resurgence Period – Dramatic increase culminating in 6,552 local cases in 2024
- 2025: Continuation Phase – Current data suggests sustained high activity
Travel vs. Local Transmission Shift:
- Historical Pattern (2010-2019): Local cases dominated during outbreak years, travel cases typically <1,500 annually
- Recent Pattern (2020-2024): Both transmission types increasing simultaneously
- 2024 Record: 3,684 travel cases (record) + 6,552 local cases = 10,236 total
- 2025 Projection: Current pace suggests another high-burden year
- Sustained High Case Numbers: With over 2,000 cases by mid-June, 2025 appears to be maintaining elevated dengue activity.
- High Hospitalization Rates: Nearly half of cases requiring hospitalization indicates significant healthcare system impact.
- DENV-3 Dominance: The overwhelming prevalence of DENV-3 may influence future outbreak patterns and vaccine considerations.
- Broad Age Distribution: Cases across all age groups suggest widespread exposure risk.
Prevention Remains Critical
Given these statistics, the CDC continues to emphasize prevention through:
| Prevention Strategy | Method | Effectiveness Level |
|---|---|---|
| Personal Protection | EPA-registered repellents, protective clothing | High |
| Environmental Control | Remove standing water, maintain sanitation | High |
| Travel Precautions | Enhanced awareness for endemic area travel | Moderate |
| Community Mosquito Control | Systematic breeding site elimination | High |
| Healthcare Awareness | Provider education on diagnosis/reporting | Moderate |
- Mosquito bite prevention: Using EPA-registered repellents, protective clothing, and environmental controls
- Travel precautions: Enhanced awareness for travelers to dengue-endemic areas
- Community mosquito control: Eliminating standing water breeding sites
Looking Forward
As 2025 progresses, continued surveillance will be crucial for tracking trends, identifying outbreaks, and guiding public health responses. The current data underscores that dengue remains a significant public health concern in the United States, requiring ongoing vigilance from healthcare providers, public health officials, and the general public.
| Surveillance Priority | Current Status | Historical Context | Future Action Needed |
|---|---|---|---|
| Case Detection | 2,096 cases reported | 55,767 cases (2010-2024) | Enhanced testing and reporting |
| Serotype Monitoring | 85% DENV-3 dominance | Limited historical serotype data | Track serotype shifts |
| Local Transmission | Increasing in 5+ states | 6,552 local cases in 2024 | Expand vector control |
| Travel Surveillance | Ongoing risk | 3,684 travel cases in 2024 | Strengthen border health measures |
| Healthcare Capacity | 45% hospitalization rate | No historical comparison | Prepare for surge capacity |
| Endemic Risk Assessment | Rising concern | Cyclical patterns observed | Develop long-term strategies |
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
